California, USA (CU)_ Tarsier Pharma, an advanced clinical stage pharmaceutical business specializing on the research and marketing of innovative treatments for blinding ocular disorders, developed and launched a special education website namely, www.uveiticglaucoma.com, dedicated especially to uveitic glaucoma. It is a public education website that creates awareness about the condition uveitic glaucoma.
Uveitic glaucoma is a late-stage illness that consists of two different eye diseases, each of which is severe and complicated in its own way. They are, non-infectious uveitis, which is an inflammatory ocular disease, and glaucoma, which is a category of eye disorders that affect the optic nerve. January has been marked as Glaucoma Awareness Month.
Ms. Ruti Friedel, BD and Community Manager of Tarsier Pharma, spoke about the blinding disease and the necessity of creating awareness for it. He also expressed delight over launching the website. He said, “Uveitic glaucoma is a severe and blinding disease, yet still under-researched and despite the devastating outcome of this condition, it is not well appreciated outside the specialized community of uveitis specialists and the struggling patients. With this in mind, we are happy to take the lead in increasing awareness of the condition by launching this dedicated website for the benefit of the general public”.
Dr. Stephen Foster, Key Opinion Leader in uveitis and a Principal Investigator in Tarsier’s phase-3 clinical study TRS4VISION in people with uveitis and uveitic glaucoma, expressed hopes for the website and the importance of creating awareness for the eye disease. He added, “As a result of uveitis alone being a rare ocular disease, the familiarity with one of its main and most devastating complications, uveitic glaucoma, is low; even among the general Ophthalmology community and stakeholders. Consequently, it is important to shed some light about its unique complexity, worse prognosis, and great challenges in treatment. We hope that Tarsier’s development efforts will contribute eventually to introduce optimal therapies for this patient population.”